Evidence map›Paper›PMID 35370989›Full record

ReviewFrontiers in endocrinology2022

Stem Cell Transplantation in the Treatment of Type 1 Diabetes Mellitus: From Insulin Replacement to Beta-Cell Replacement.

Xin-Xing Wan, Dan-Yi Zhang, Md Asaduzzaman Khan, Sheng-Yuan Zheng, Xi-Min Hu, Qi Zhang, Rong-Hua Yang, Kun Xiong

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Advancements in diabetes research and stem cell therapy: a concise review.Journal of diabetes and metabolic disorders · 2025
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Xin-Xing WanDepartment of Endocrinology, Third Xiangya Hospital, Central South University, Changsha, China.
Dan-Yi ZhangClinical Medicine Eight-Year Program, Xiangya School of Medicine, Central South University, Changsha, China.
Md Asaduzzaman KhanThe Research Centre for Preclinical Medicine, Southwest Medical University, Luzhou, China.
Sheng-Yuan ZhengClinical Medicine Eight-Year Program, Xiangya School of Medicine, Central South University, Changsha, China.
Xi-Min HuDepartment of Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha, China.
Qi ZhangDepartment of Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha, China.
Rong-Hua YangDepartment of Burn and Plastic Surgery, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Kun XiongDepartment of Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha, China.
Central South University · CNGuangzhou Medical University · CNSouthwest Medical University · CNThird Xiangya Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 1 diabetes mellitus (T1DM) is an autoimmune disease that attacks pancreatic β-cells, leading to the destruction of insulitis-related islet β-cells. Islet β-cell transplantation has been proven as a curative measure in T1DM. However, a logarithmic increase in the global population with diabetes, limited donor supply, and the need for lifelong immunosuppression restrict the widespread use of β-cell transplantation. Numerous therapeutic approaches have been taken to search for substitutes of β-cells, among which stem cell transplantation is one of the most promising alternatives. Stem cells have demonstrated the potential efficacy to treat T1DM by reconstitution of immunotolerance and preservation of islet β-cell function in recent research. cGMP-grade stem cell products have been used in human clinical trials, showing that stem cell transplantation has beneficial effects on T1DM, with no obvious adverse reactions. To better achieve remission of T1DM by stem cell transplantation, in this work, we explain the progression of stem cell transplantation such as mesenchymal stem cells (MSCs), human embryonic stem cells (hESCs), and bone marrow hematopoietic stem cells (BM-HSCs) to restore the immunotolerance and preserve the islet β-cell function of T1DM in recent years. This review article provides evidence of the clinical applications of stem cell therapy in the treatment of T1DM.

Indexed as

Diabetes Mellitus, Type 1Insulin-Secreting CellsIslets of LangerhansHumansInsulinStem Cell TransplantationInsulinimmunotolerancestem celltransplantationtype 1 diabetes mellitusβ-cell

Identifiers

PMID35370989
PMCPMC8972968
OpenAlexW4220900001

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.